Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2026
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026
Comment on: Hospital-Based Careers in Pediatric Hematology-Oncology: The State of the Field and Future Needs Impact of a Pediatric Onco-Hospitalist Model on Inpatient Oncology Care Delivery.
Journal: Pediatric blood & cancer
Published: May 14, 2026
Complexities in the Diagnostic Evaluation and Treatment of Infant Hemophagocytic Lymphohistiocytosis.
Journal: Hematology reports
Published: April 14, 2026
Midostaurin-Cladribine Therapy for Neonatal Aggressive Systemic Mastocytosis.
Journal: Pediatric blood & cancer
Published: February 18, 2026
Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.
Journal: Leukemia
Published: December 31, 2025
Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.
Journal: British journal of haematology
Published: August 21, 2025
Synchronous Mediastinal Germ Cell Tumor with Sarcomatous Transformation and Acute Myeloid Leukemia.
Journal: Pediatric blood & cancer
Published: August 18, 2025
Uncommon Presentation and Therapeutic Strategies in Pediatric Relapsed/Refractory ALK-Positive ALCL.
Uncommon Presentation and Therapeutic Strategies in Pediatric Relapsed/Refractory ALK-Positive ALCL.
Journal: Journal of pediatric hematology/oncology
Published: August 05, 2025
Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma With Unusually Long Clinical Course.
Journal: Journal of cutaneous pathology
Published: July 23, 2025
High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition.
Journal: Molecular & cellular proteomics : MCP
Published: May 08, 2025
Last Updated: 09/26/2026